Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	OptiNose	Atossa Therapeutics	Concert Pharmaceuticals	Medicenna Therapeutics	Iterum Therapeutics
Symbol	NASDAQ:OPTN	NASDAQ:ATOS	NASDAQ:CNCE	NASDAQ:MDNA	NASDAQ:ITRM
Price Information
Current Price	$3.51	$1.63	$4.41	$3.97	$1.10
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.6	1.2	1.7	0.7	1.3
Analysis Score	3.3	3.5	3.5	3.5	3.3
Community Score	2.4	2.5	2.7	0.0	2.4
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.0	1.7	0.0	0.0
Earnings & Valuation Score	0.6	0.0	0.6	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$18.00	$7.50	$20.50	$10.00	$3.25
% Upside from Price Target	412.82% upside	360.12% upside	364.85% upside	151.89% upside	195.45% upside
Trade Information
Market Cap	$185.84 million	$196.94 million	$141.89 million	$210.23 million	$194.13 million
Beta	1.03	2.34	0.77	1.39	1.49
Average Volume	440,043	21,996,809	484,403	211,386	25,012,971
Sales & Book Value
Annual Revenue	$34.63 million	N/A	$1.08 million	N/A	$40,000.00
Price / Sales	5.37	N/A	131.38	N/A	4,853.15
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$1.48 per share	$1.37 per share	$4.26 per share	$0.77 per share	($1.88) per share
Price / Book	2.37	N/A	1.04	N/A	-0.59
Profitability
Net Income	$-110,050,000.00	$-17,240,000.00	$-78,170,000.00	$-6,220,000.00	$-103,130,000.00
EPS	($2.63)	N/A	($3.29)	($0.19)	($7.10)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	∞	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-230.14%	N/A	-921.38%	N/A	N/A
Return on Equity (ROE)	-294.64%	-130.58%	-55.20%	-40.19%	N/A
Return on Assets (ROA)	-59.29%	-108.14%	-44.83%	-37.66%	-179.51%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	3.79%	N/A	N/A	N/A	N/A
Current Ratio	3.98%	7.23%	18.51%	26.75%	0.30%
Quick Ratio	3.76%	7.23%	18.51%	26.75%	0.30%
Ownership Information
Institutional Ownership Percentage	62.93%	6.87%	69.68%	3.90%	10.14%
Insider Ownership Percentage	38.00%	33.21%	10.10%	N/A	22.10%
Miscellaneous
Employees	204	4	71	7	7
Shares Outstanding	52.95 million	120.82 million	32.17 million	52.96 million	176.48 million
Next Earnings Date	5/6/2021 (Estimated)	5/12/2021 (Estimated)	4/29/2021 (Estimated)	5/21/2021 (Estimated)	5/13/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable	Not Optionable

Source	Headline
	For Iterum Therapeutics plc [ITRM], Analyst sees a rise to $2.50. What next? dbtnews.com - April 13 at 8:14 PM
	Iterum Therapeutics plc (NASDAQ:ITRM) Is An Exciting Stock stocksregister.com - April 12 at 6:15 PM
	Shares of Iterum Therapeutics plc (NASDAQ:ITRM) lost -8.33% in a month. marketingsentinel.com - April 12 at 8:14 AM
	BRIEF-Iterum Therapeutics Says FDA Needs More Time To Review Materials Provided In Support Of NDA msn.com - April 10 at 7:06 PM
	Why Iterum (ITRM) Stock Is Plunging Today? benzinga.com - April 9 at 11:17 AM
	Iterum Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference finance.yahoo.com - April 6 at 9:28 AM
	Short Interest in Iterum Therapeutics plc (NASDAQ:ITRM) Rises By 45.2% americanbankingnews.com - April 1 at 8:28 AM
	Iterum Therapeutics plc (NASDAQ:ITRM) is up 43.58 percent year-to-date, but analysts anticipate a price rally stocksregister.com - March 26 at 3:11 PM
	12-month price target for Iterum Therapeutics plc (NASDAQ:ITRM) now sits at $2.5 marketingsentinel.com - March 26 at 10:11 AM
	Iterum Therapeutics Stock Looks Like a High-Risk Name Here feedproxy.google.com - March 22 at 9:54 AM
	Iterum Therapeutics’ Science Won’t Prevent Its Volatility feedproxy.google.com - March 18 at 6:12 AM
	Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors finance.yahoo.com - March 16 at 10:27 AM
	ITRM Stock Price Increased 1.94% After Hours: Why It Happened pulse2.com - March 14 at 12:49 PM
	Iterum Therapeutics plc (ITRM) CEO Corey Fishman on Q4 2020 Results - Earnings Call Transcript seekingalpha.com - March 14 at 7:48 AM
	ITRM Stock Price Increases Over 5% Pre-Market: Why It Happened pulse2.com - March 12 at 10:05 PM
	Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results finance.yahoo.com - March 12 at 10:05 PM
	Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host ... apnews.com - March 5 at 7:01 PM
	Unfavorable Earnings Profile Doesn’t Bode Well for Iterum Therapeutics Stock feedproxy.google.com - March 2 at 12:21 PM
	Iterum Therapeutics to Present in Upcoming Investor Conferences finance.yahoo.com - February 19 at 8:09 PM
	Iterum Therapeutics plc Announces Exercise of Underwriter's Option to Purchase Additional Ordinary Shares marketwatch.com - February 11 at 9:06 AM
	ITRM Stock Price Increases Over 15% Pre-Market: Why It Happened pulse2.com - February 11 at 9:06 AM
	Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares ... apnews.com - February 11 at 4:05 AM
	Iterum Therapeutics plc Announces Exercise of Underwriter’s Option to Purchase Additional ... apnews.com - February 11 at 4:05 AM
	Iterum Therapeutics plc Announces Exercise of Underwriter’s Option to Purchase Additional Ordinary Shares finance.yahoo.com - February 10 at 10:20 PM
	Iterum Therapeutics Presses Capital Raise Button To Support Potential Sulopenem Launch Activities feeds.benzinga.com - February 10 at 6:47 AM

Date	Company	Brokerage	Action
7/16/2020	OptiNose	Piper Sandler	Reiterated Rating
7/16/2020	OptiNose	Royal Bank of Canada	Reiterated Rating
3/5/2020	OptiNose	Cantor Fitzgerald	Lower Price Target
12/18/2019	OptiNose	Cowen	Initiated Coverage
8/13/2019	OptiNose	BMO Capital Markets	Lower Price Target
4/23/2019	OptiNose	Piper Jaffray Companies	Set Price Target
9/18/2020	Atossa Therapeutics	Maxim Group	Reiterated Rating
9/17/2020	Atossa Therapeutics	Ascendiant Capital Markets	Initiated Coverage
5/15/2018	Atossa Therapeutics	Noble Financial	Set Price Target
2/2/2021	Concert Pharmaceuticals	Truist	Lower Price Target
2/2/2021	Concert Pharmaceuticals	HC Wainwright	Reiterated Rating
12/16/2020	Concert Pharmaceuticals	Berenberg Bank	Initiated Coverage
11/4/2020	Concert Pharmaceuticals	JMP Securities	Initiated Coverage
10/2/2020	Concert Pharmaceuticals	Mizuho	Reiterated Rating
3/30/2020	Concert Pharmaceuticals	Jefferies Financial Group	Initiated Coverage
2/27/2020	Concert Pharmaceuticals	Stifel Nicolaus	Downgrade
1/22/2020	Concert Pharmaceuticals	SunTrust Banks	Reiterated Rating
9/30/2019	Concert Pharmaceuticals	Janney Montgomery Scott	Reiterated Rating
12/17/2020	Medicenna Therapeutics	Oppenheimer	Initiated Coverage
8/24/2020	Medicenna Therapeutics	Brookline Capital Management	Reiterated Rating
8/24/2020	Medicenna Therapeutics	Bloom Burton	Reiterated Rating
10/1/2020	Iterum Therapeutics	SVB Leerink	Boost Price Target
5/14/2020	Iterum Therapeutics	Needham & Company LLC	Reiterated Rating
1/21/2020	Iterum Therapeutics	G.Research	Downgrade
1/21/2020	Iterum Therapeutics	Gabelli	Downgrade

(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources